Innovative Vaccine Strategy: Self-Adjuvanting Conjugate Vaccines
- PMID: 36587070
- DOI: 10.1007/978-1-0716-2910-9_5
Innovative Vaccine Strategy: Self-Adjuvanting Conjugate Vaccines
Abstract
Self-adjuvanting vaccines, covalent conjugates between antigens and adjuvants, are chemically well-defined compared with conventional vaccines formulated through mixing antigens with adjuvants. Innate immune receptor ligands effectively induce acquired immunity through the activation of innate immunity, thereby enhancing host immune responses. Thus, innate immune receptor ligands are often used as adjuvants in self-adjuvanting vaccines. In a self-adjuvanting vaccine, the covalent linkage of antigen and adjuvant enables their simultaneous uptake into immune cells where the adjuvant consequently induces antigen-specific immune responses. Importantly, self-adjuvanting vaccines do not require immobilization to carrier proteins or co-administration of additional adjuvants and thus avoid inducing undesired immune responses. Because of these excellent properties, self-adjuvanting vaccines are expected to be candidates for next-generation vaccines. Here, we take an overview of vaccine adjuvants, mainly focusing on those utilized in self-adjuvanting vaccines and then we review recent reports on self-adjuvanting conjugate vaccines.
Keywords: Acquired immunity; Adjuvant; Conjugate vaccine; Innate immunity; Self-adjuvanting.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Recent advances in self-adjuvanting glycoconjugate vaccines.Drug Discov Today Technol. 2020 Dec;37:61-71. doi: 10.1016/j.ddtec.2020.11.006. Epub 2020 Dec 10. Drug Discov Today Technol. 2020. PMID: 34895656 Review.
-
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.J Virol. 2017 Jan 31;91(4):e01844-16. doi: 10.1128/JVI.01844-16. Print 2017 Feb 15. J Virol. 2017. PMID: 27928002 Free PMC article.
-
Semisynthetic, self-adjuvanting vaccine development: Efficient, site-specific sortase A-mediated conjugation of Toll-like receptor 2 ligand FSL-1 to recombinant protein antigens under native conditions and application to a model group A streptococcal vaccine.J Control Release. 2020 Jan 10;317:96-108. doi: 10.1016/j.jconrel.2019.11.018. Epub 2019 Nov 21. J Control Release. 2020. PMID: 31758971
-
Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2.J Med Chem. 2023 Jan 26;66(2):1467-1483. doi: 10.1021/acs.jmedchem.2c01642. Epub 2023 Jan 10. J Med Chem. 2023. PMID: 36625758
-
Self-adjuvanting cancer nanovaccines.J Nanobiotechnology. 2022 Jul 26;20(1):345. doi: 10.1186/s12951-022-01545-z. J Nanobiotechnology. 2022. PMID: 35883176 Free PMC article. Review.
Cited by
-
Diacetyl strategy for synthesis of NHAc containing glycans: enhancing glycosylation reactivity via diacetyl imide protection.Front Chem. 2023 Dec 5;11:1319883. doi: 10.3389/fchem.2023.1319883. eCollection 2023. Front Chem. 2023. PMID: 38116104 Free PMC article. Review.
References
-
- Heinz FX, Stiasny K (2021) Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines 6:104 - DOI
-
- Singh M, O’Hagan D (1999) Advances in vaccine adjuvants. Nat Biotechnol 17:1075–1081 - DOI
-
- Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82:488–496 - DOI
-
- Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33:492–503 - DOI
-
- Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5:396–397 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical